/
Cannabinoid-Receptor Interacting Protein 1a (CRIP1a Cannabinoid-Receptor Interacting Protein 1a (CRIP1a

Cannabinoid-Receptor Interacting Protein 1a (CRIP1a - PowerPoint Presentation

mitsue-stanley
mitsue-stanley . @mitsue-stanley
Follow
370 views
Uploaded On 2018-03-06

Cannabinoid-Receptor Interacting Protein 1a (CRIP1a - PPT Presentation

effects on CB1 Inverse Agonists Erin Cochran Endocannabinoid System Pharmacology Terms Basal or Constitutive activity physiological response in the absence of an agonist or inverse ID: 640920

agonists stimulation hek inverse stimulation agonists inverse hek crip1a ligand binding hcb1 basal agonist cb1 activity modulation gtp sr141716a

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Cannabinoid-Receptor Interacting Protein..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Cannabinoid-Receptor Interacting Protein 1a (CRIP1a) effects on CB1 Inverse Agonists

Erin CochranSlide2
Slide3

Endocannabinoid SystemSlide4

Pharmacology Terms

Basal

or

Constitutive

activity- physiological response

in the absence of an agonist or inverse agonistAgonist-

ligand

that increases basal activity

Inverse

Agonist- a ligand that inhibits or eliminates basal activitySlide5

CB1 CRIP1a

Ahmed et al. 2015Slide6

Current Research

Smith et al. 2015

Full agonist: WIN

Partial agonists: MAE and THC

Inverse agonist: RIMSlide7

What Triggers CRIP1a Modulation?

Extreme ends of stimulation are modulated (full agonists and inverse agonists)

Moderate stimulation is not modulated (partial agonists)

Is CRIP1a modulation triggered by the intrinsic efficacy of a ligand or if

stimulation caused by the ligand

exceeds a range?Slide8

G-protein Coupled Receptor Activation

Harrison and

Traynor

2003Slide9

[35S]GTP

g

S

Binding Assay

Harrison and

Traynor

2003Slide10

Background Experiments

Transfect

Human Embryonic Kidney (HEK)

cell lines

hCB1-HEK

hCB1-HEK-CRIP1aReceptor Density[

3H]SR141716A binding assayControl

Basal binding

[

35

S]

GTP

gS binding assay without ligands presentBaselineSlide11

Inverse Agonists

Pertwee

2005Slide12

ExperimentCell Line Reactions

hCB1-HEK + inverse agonists +

[

35

S]GTP

gShCB1-HEK-CRIP1a + inverse agonists + [

35S]GTPg

S

Reaction stopped by vacuum filtration

Measure CB1 receptors bound with

[

35

S]GTPgS with scintillation counterSlide13

Data AnalysisNet Stimulation = Ligand Stimulation – Basal Binding

Percent Stimulation = (Net Stimulation / Basal Binding) X 100

Compare percent stimulation between hCB1-HEK and hCB1-HEK-CRIP1a

Compare percent stimulation between the ligands in hCB1-HEK-CRIP1a Slide14

Triggering CRIP1a Modulation

Intrinsic efficacy of ligand

All three inverse agonists stimulation will be reduced to the same degree

Reduction of Stimulation

SR141716A = AM251 = AM281

Extreme ends of range

Stimulation caused by the less potent inverse agonists will be reduced less than the more potent inverse agonists

Reduction of Stimulation

SR141716A > AM251 > AM281Slide15

Questions?